paroxysmal nocturnal hemoglobinuria statistics

At the time of the study, Anita Hill had received honoraria and consulting fees from Alexion Pharmaceuticals, Inc. Ataulfo Gonzalez-Fernandez, Emilio Ojeda Gutierrez, and Richard Wells have received honoraria and consulting fees from Alexion Pharmaceuticals, Inc. (Boston, MA, USA).Ĭompeting interests: The authors of this paper have read the journal’s policy and have the following competing interests: Austin Kulasekararaj, Anna Gaya, F. Medical writing and editorial support were provided by ApotheCom (Yardley, PA, USA) and funded by Alexion Pharmaceuticals, Inc.

The decision to submit the manuscript to PLoS One was made independently by the authors with no influence from the sponsor. The sponsor (Alexion Pharmaceuticals, Inc.) had no additional role and was not involved in interpretation of the data, reporting of the results, or preparation of the manuscript. The specific roles of the authors are articulated in the author contributions section, and the contributors are acknowledged in the Acknowledgments. Alexion Pharmaceuticals, Inc., provided support in the form of salaries and stocks to authors (Ioannis Tomazos and Masayo Ogawa) and contributors (Ji Yu, Ke Zu, Scott Rottinghaus, and Simu Thomas) of this study. The Data Request Form is available on the Alexion website ( ).įunding: This study was funded by Alexion Pharmaceuticals, Inc. Further details regarding data availability and instructions for requesting information are available in the Alexion Clinical Trials Disclosure and Transparency Policy at. Qualified academic investigators may request participant-level clinical data and supporting documents (statistical analysis plan and protocol) pertaining to Alexion-sponsored studies. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: Alexion will consider requests for disclosure of clinical study participant-level data provided that participant privacy is assured through methods such as data de-identification, pseudonymization, or anonymization (as required by applicable law), and if such disclosure was included in the relevant study informed consent form or similar documentation. Received: NovemAccepted: JPublished: September 4, 2020Ĭopyright: © 2020 Peipert et al. PLoS ONE 15(9):Įditor: David Dingli, Mayo Clinic, UNITED STATES

(2020) Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

Citation: Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, et al.

Paroxysmal nocturnal hemoglobinuria statistics